A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

by | May 27, 2026 | Clinical Trials | 0 comments

​ Conditions: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia

Interventions: Drug: Olutasidenib

Sponsors: Kissei Pharmaceutical Co., Ltd.

Recruiting Conditions: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
Interventions: Drug: Olutasidenib
Sponsors: Kissei Pharmaceutical Co., Ltd.
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *